BLOOMFIELD, N.J.--(BUSINESS WIRE)--Alfacell Corporation (NASDAQ: ACEL) today announced results from further detailed analysis of the company’s previously reported Phase IIIa clinical trial of ONCONASE® (ranpirnase) versus doxorubicin for the treatment of unresectable malignant mesothelioma (UMM). The post-hoc analysis found that patients treated with ONCONASE had greater median survival times than patients treated with doxorubicin alone using the validated prognostic scoring systems of both the Cancer and Leukemia Group B (CALGB) and European Organization for Research and Treatment of Cancer (EORTC). These scoring systems were not the original endpoints of the Phase IIIa trial. The new findings were presented on Sunday, October 22 at the 8th International Conference of the International Mesothelioma Interest Group (IMIG), held in Chicago, IL at the Sheraton Chicago Hotel and Towers, by Joachim von Pawel, M.D, Chief of Oncology, Askleplos Specialized Clinic, Center for Pneumology and Thoracic Surgery, Gauting, Germany. Dr. von Pawel’s presentation was entitled, “A Comparison of CALGB and EORTC Paradigms in the Assessment of ONCONASE® for the Treatment of Unresectable Malignant Mesothelioma (UMM).”
